Novel Strategies in the Development of New Therapies, Drug Substances and Drug Carriers

Edited by
July 2022
450 pages
  • ISBN978-3-0365-4646-9 (Hardback)
  • ISBN978-3-0365-4645-2 (PDF)

This book is a reprint of the Special Issue Novel Strategies in the Development of New Therapies, Drug Substances and Drug Carriers that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology

This book is conceived to promote synergy between research and industrial activities in the design and development of new drugs and, therefore, is not limited to any specific aspect of development. It covers the entire process from the identification of a molecular target, studies of drug–protein interactions, the modeling and optimization of the functional activity, design and chemical synthesis, biological evaluation, and the development of new pharmaceutical carriers.The original articles and reviews are focused on the design and development of new anticancer treatments, new anticancer low-molecular-weight agents as potential drug substances, and the elucidation of their mechanisms of action. The book also includes studies on novel modulators of the serotonergic system used to treat central nervous system disorders, novel agents against infectious diseases, and the development of anti-plasmodial and anti-inflammatory agents. The successful identification of new compounds for development as drug substances comes from rich sources of medicinal plants and medicinal chemistry approaches.

  • Hardback
© 2022 by the authors; CC BY-NC-ND license
alpha-ketoglutarate; cell cycle; apoptosis; JNK; cell migration; cell invasion; TGF-β; VEGF; glycoconjugates; methotrexate; cancer treatment; glucose metabolism; drug design and discovery; anticancer drugs; targeted therapy; Warburg effect; antidepressants; pyrido[1,2-c]pyrimidines; dual 5-HT1A/SERT activity; drug design; anticancer activity; lung cancer; resveratrol; PRI-2191; vitamin D; active substance delivery systems; biomedical hydrogels; active substance-controlled release; genistein; hydrogels for cosmetology; hydrogels for dermatology; transdermal active substance delivery systems; histone deacetylase (HDAC); depression; biomarker; anti-depressant therapy; human DNA topoisomerase; cancer; drug; molecular docking; synthesis; fluorine; vitamin D3; metabolite; A-ring; CD-ring; side-chain; anticancer drugs; nanoparticles; molecular modeling; oxidation mechanisms; electrochemistry; MALDI; spectroscopic data; cytotoxic study; self-assembled monolayer; gold electrode; antidepressants; drug design; dual 5-HT1A/SERT activity; multimodal activity; calcium-sensing receptor; enantiomer; calcimimetic; calcilytic; colon cancer; stereospecificity; HT-29; IL-8; inflammation; cyclooxygenase; 1,2,4-triazole; pyridazinone; SAR; molecular docking; anti-inflammatory activity; antioxidant activity; ADME; anticancer drug; antimicrobial peptide (AMP); dermaseptin; frog skin peptides; LHRH; prostate cancer; Phyllomedusa bicolor; therapeutic peptides; copper (II) complexes; thiourea; cytotoxic activity; proteome analysis; antimicrobial activity; major latex protein; Chelidonium majus; greater celandine; defense-related proteins; alkaloids; molecular docking; cancer cells; vitamin D; vitamin D receptor; split luciferase-based biosensor; CYP24A1-dependent metabolism; CYP27B1; rickets; genome editing; vitamin D biology and action; transcription; ChIP-chip analysis; distal enhancers; histone H3 acetylation; RNA polymerase II; analogue actions at genes; vitamin D hormone (1,25(OH)2D3); latex; antiviral proteins; antimicrobial compounds; cytotoxicity; drug discovery; Chelidonium majus; CRISPR/Cas9; tetrahydro-β-carbolines; Plasmodium falciparum (P. falciparum); antimalarial; antiparasitic agents; cytotoxicity; hemolysis; molecular docking; vitamin D; vitamin D analogs; 25 vitamin D 24-hydroxylase; CYP24A1; proliferation; high-grade serous ovarian cancer cells; gold; Au(III) complex; colorectal cancer; anticancer drugs; organometallic; cancer therapy; cytotoxicity; metallodrugs; n/a